SLC10A2 and Alagille syndrome: Maralixibat (MRX) is a minimally absorbed, selective inhibitor of the ileal bile acid transporter (IBAT), which interrupts the enterohepatic circulation of bile acids (BAs), thereby reducing the highly elevated levels of circulating serum bile acids (sBAs) in cholestasis, and is shown to be effective in cholestatic patients with Alagille syndrome [7].